Jabre Capital Partners’s Exact Sciences EXAS Stock Holding History

Jabre Capital Partners’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-12,500	Closed	-$504K	–	177
2018 Q1	$504K	Buy	+12,500	New	+$610K	0.11%	110

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Jabre Capital Partners's EXAS Position: Q2 2018 in Review

Jabre Capital Partners sold out of Exact Sciences (EXAS) in Q2 2018, closing a stake of 12,500 shares — an estimated $504K sold.

Jabre Capital Partners first reported a position in EXAS in Q1 2018 and held it in 1 quarter. The position peaked at $504K in Q1 2018. 349 funds tracked by Wall St. Rank hold EXAS as of Q2 2018.

Jabre Capital Partners reported no remaining Exact Sciences position as of Q2 2018 after selling out during the quarter.
Jabre Capital Partners sold 12,500 Exact Sciences shares in Q2 2018, an estimated $504K.
Jabre Capital Partners first reported a position in Exact Sciences in Q1 2018 and held it in 1 quarter.
Jabre Capital Partners's Exact Sciences position peaked at $504K in Q1 2018.
349 funds tracked by Wall St. Rank held Exact Sciences as of Q2 2018.

Based on Jabre Capital Partners's 13F filing for Q2 2018, filed 14 Aug 2018.